This year’s timely conference will cover over 16 in-depth sessions and case study examples including: • Novel Techniques for Formulating a Respiratory Drug Development Pipeline • Differences in the Development of Small vs. Large Molecules • Evolving Clinical Endpoints in the Development of Inhaled Corticosteroids • Clinical Outcomes of PD4 Inhibitors: Valuable Lessons Learned • Improving the Management of Patient Care in Asthma • Developing Product Design for Addressing Patient Adherence and Compliance And much more including 4+ hours of scheduled networking, insightful interactive panel discussions and a series of interactive workshops. Learn Best Practice Strategies On How To: • Assess the need for innovative drug development pipelines in the respiratory market • Uncover modern techniques for formulating a respiratory drug development pipeline • Discover if we need new bronchodilators and anti-inflammatory drugs for the treatment of Asthma and COPD • Develop and enhance product design for addressing patient adherence and compliance • Discover effective strategies for improving the management of patient care in Asthma

1. Register by April 3rd and SAVE up to $698
Asthma Gain valuable insights into new
groundbreaking advances within the
respiratory drug development market
& COPD
TM
June 24-26, 2009
Philadelphia, PA
See
inside for the
All-Access
Pass discount!
Learn from Leading
Innovators Including:
Heribert Staudinger, PhD, Vice President,
Clinical Development, Schering Plough
Nestor A. Molfino, MD, Vice President, Clinical
Development, Respiratory Diseases, Allergy and
Learn Best Practice Strategies On How To: Inflammation, MedImmune
Theodore F. Reiss, MD, Vice President of Clinical
• Assess the need for innovative drug development pipelines in the Research, Merck Research Laboratories
respiratory market Adam Wanner, MD, Professor, Principal
Investigator, University of Miami Miller School
• Uncover modern techniques for formulating a respiratory drug of Medicine
development pipeline Shahin Sanjar, PhD, Head, Pipeline Sourcing,
Nycomed US Inc.
• Discover if we need new bronchodilators and anti-inflammatory
Mark Parry-Billings, PhD, Chief Executive
drugs for the treatment of Asthma and COPD Officer, Topigen Pharmaceuticals
• Develop and enhance product design for addressing patient Chris O’Brien, PhD, Vice President, Respiratory &
adherence and compliance Inflammation Therapeutic Area, AstraZeneca
Kevin B. Bacon, PhD, President, Founder and
• Discover effective strategies for improving the management of Chief Scientific Officer, Axikin Pharmaceuticals
patient care in Asthma Colin Scott, MD, Global Brand Medical Director,
Novartis
Michael A. McAlexander, PhD, Senior Research
Fellow, CEDD, GlaxoSmithKline
Media Partners:
Lawrence de Garavilla, PhD, Research Fellow,
Drug Discovery , Inflammation and Pulmonary
Diseases Team, Johnson and Johnson
Jonathan E. Phillips, Ph.D, Principal Scientist,
Respiratory and Inflammation, Schering-Plough
Research Institute
Navin L. Rao, PhD, Senior Scientist, Drug
www.iqpc.com/us/asthma Discovery, Inflammation, Johnson & Johnson

2. Asthma Gain valuable insights into new groundbreaking advances
within the respiratory drug development market
& COPD
TM
June 24-26, 2009 | Philadelphia, PA
Who Will you Meet at the
Conference?
Directors, Heads, Scientists, Chemists,
Research Leaders/Fellows/Advisors, &
Managers working in the pharmaceutical or
Dear Colleagues, biotech industries within:
• Respiratory Therapeutics
Respiratory diseases including Asth • Research & Development
ma are becoming more common,
children, therefore the demand for especially in • Inflammation
continued development in respirato
discovery and development arena ry drug • Clinical Development
has grown significantly in recent year
commercial drug development mar s. The • Regulatory Affairs
ket in this area continues to grow Pulmonology
corticosteroid/long-acting bronchod with inhaled •
ilator combinations set to be the lead • Drug Discovery
value in 2014, and an estimated 300 ing class by
million people in the world will be • Respiratory Illness
from Asthma, with COPD on the suffering
rise. • Drug Delivery
• Project Management
This year’s timely conference will cove • Allergy Therapeutics
r over 16 in-depth sessions and case
examples including: study • Preclinical Development
• Novel Tech
• Portfolio/Lifecycle Management
niques for Formulating a Respirato
ry Drug Development Pipeline
• Differences
in the Development of Small vs. Larg
e Molecules
• Evolving Clin
ical Endpoints in the Developmen A special thank you to our
t of Inhaled Corticosteroids
• Clinical Out
comes of PD4 Inhibitors: Valuable
Lessons Learned
advisory board
• Improving
the Management of Patient Care Kevin B. Bacon, PhD, President, Founder and
in Asthma Chief Scientific Officer, Axikin
• Developing
Product Design for Addressing Patie
nt Adherence and Compliance Pharmaceuticals
Heribert Staudinger, PhD, Vice President,
And much more including 4+ hou Clinical Development, Schering Plough
rs of scheduled networking, insightfu
panel discussions and a series of inte l interactive
ractive workshops. Shahin Sanjar, PhD, Head, Pipeline Sourcing,
Nycomed US Inc.
Engage in dynamic conversation with Mark Parry-Billings, PhD, Chief Executive
your industry peers at our multiple Officer, Topigen Pharmaceuticals
sessions and work closely with man networking
y respiratory drug discovery and deve Ewan Walters, PhD, Medical Director, Teva UK
industry leaders including AstraZen lopment
eca, Merck, Johnson & Johnson, Med Dzelal Serdarevic, PhD, Director, A&R
Schering Plough, Nycomed, GlaxoSm Immune,
ithKline, Novartis and many more, Therapeutic Area, Clinical R&D, Pfizer
series of medical device designers, including a
delivery experts and academic part Reza Farienfar, Director, Business
sure to register yourself and a team icipants. Be Development, Cardinal Health
of key people for this important even
t today! Gerhard Scheuch, PhD, Chief Executive
We look forward to seeing you in Officer, Activaero GmbH
Philadelphia in June!
Best Regards,
Sponsorship and Exhibition
Opportunities
teractive
P . - Highly in
Sponsorships and exhibits are excellent
.S opportunities for your company to showcase its
e
and informativ products and services to high-level, targeted
post-confe rence decision-makers attending the Asthma & COPD
e page 5 Summit. IQPC and Pharma IQ help companies like
Simon Curtis
workshops! Se yours achieve important sales, marketing and
branding objectives by setting aside a limited
for details.
Conference Director
number of event sponsorships and exhibit spaces –
www.iqpc.com/us/asthma all of which are tailored to assist your organization
in creating a platform to maximize your exposure at
the event.
For more information on sponsoring or exhibiting at
the Asthma & COPD Summit please contact Mario
Matulich at (212) 885-2719 or
sponsorship@iqpc.com.
2 1-800-882-8684 • www.iqpc.com/us/asthma

3. Main Conference Day One
Wednesday, June 24, 2009
8:00 Registration and Coffee 1:30 Panel Discussion: Improving Endpoints in COPD
Drug Development
8:50 Welcome Address and Chairman’s Opening Remarks • Discussing the pros and cons of improved X-Ray analysis
• Evaluating high resolution CT scans
9:00 Opening Keynote Presentation: Novel Techniques for • Identifying newer endpoints for evaluation
Formulating a Respiratory Drug Development Pipeline Kevin B. Bacon, PhD, President, Founder and Chief Scientific Officer,
• Accelerating the drug development pipeline Axikin Pharmaceuticals
• Identifying a set of promising candidate projects addressing gaps in Heribert Staudinger, PhD, Vice President, Clinical Development,
several stages of the drug development pipeline from fundamental Schering Plough
research to product Fred Bode, PhD, Director, Respiratory Sciences, Sepracor*
• Evaluating strategies for generating large numbers of molecular Shahin Sanjar, PhD, Senior Director, Respiratory Sciences, Nycomed
targets for drugs as well as novel molecules to attack new and existing
drug targets 2:15 Evolving Clinical Endpoints in the Development of
• Generating the interest and funding that will move a compound along Inhaled Corticosteroids
the path to eventual therapeutic approval • Discussing development of inhaled corticosteroid/long-acting beta-
Theodore F. Reiss, MD, Vice President of Clinical Research, Merck agonist combinations
Research Laboratories • Overviewing clinical endpoints
• Addressing and understanding beta-agonist safety issues/patient
9:45 Panel Discussion: Understanding and Assessing the monitoring
Need for New Drug Development Pipelines in the • Examining endpoint case study examples
Respiratory Market • Discussing the development of NMEs in asthma and COPD
• Examining pipeline pitfalls from the past: What to be aware of? • Discovering if we need new bronchodilators and anti-inflammatory
• Overviewing new respiratory therapeutic approaches: Strategies for drugs for the treatment of asthma and COPD
predicting clinical success or failure Heribert Staudinger, MD, Vice President, Clinical Development,
• Investigating compounds which may help improve control of asthma Allergy, Respiratory and Immunology,, Schering Plough
exacerbations while reducing the need for steroids and rescue
medication 3:00 Networking Break
• Evaluating the need to find novel anti-inflammatory drugs to treat
COPD to reduce exacerbations, disease progression and mortality 3:30 The Promise of PDE4 Inhibitors as Novel Anti-
• Discussing and predicting the future direction of the respiratory drug Inflammatory Agents in COPD: Valuable Lessons
discovery and development market Learnt From Clinical Studies
Nestor A. Molfino, MD, Vice President, Clinical Development, • Discussing what we can learn from animal models of COPD
Respiratory Diseases, Allergy and Inflammation, MedImmune • Identifying what we have learnt from clinical studies with PDE4
Mark Parry-Billings, PhD, Chief Executive Officer, Topigen inhibitors
Adam Wanner, MD, Professor, Principal Investigator, University of • Choosing appropriate endpoints to reflect the drug mode of action
Miami Miller School of Medicine • Treating systemic or lung disease
• Examining the place of anti-inflammatory therapy in COPD
10:30 Networking Break Shahin Sanjar, PhD, Head, Pipeline Sourcing, Nycomed US Inc.
11:00 Differences in the Development of Small vs. Large 4:15 Application of Antisense Oligonucleotides in
Molecules Asthma and COPD (Case Study)
• Summarizing the main differences between small molecules and large • Examining oligonucleotide therapeutics in respiratory disease
molecules • Displaying rationale for using a multi-target approach in asthma
• Reviewing of preclinical approaches and COPD
• Understanding of main differences in clinical development programs • Designing and pre-clinical screening of effective drug candidates
• Exploring if combination of large and small molecules is feasible • Discussing clinical positioning and findings
• Comprehending the major bottlenecks in overall development Mark Parry-Billings, PhD, Chief Executive Officer, Topigen
Nestor A. Molfino, MD, Vice President, Clinical Development,
Respiratory Diseases, Allergy and Inflammation, MedImmune 5:00 COPD: New Lessons from Alpha-1 Antitrypsin
Deficiency (Case Study)
11:45 Assessment of Safety in Novel Respiratory Delivery • Appreciating the global COPD problem and the lack of disease-
Systems: Lessons from the Exubera Development modifying drug therapy for COPD
Program • Understanding that alpha-1 antitrypsin deficiency, a rare genetic
• Understanding the issues of assessing respiratory safety in systemic disease with a well characterized pathogenesis, has the same
therapies delivered through the lung pulmonary phenotype as common COPD and therefore can serve as
• Discussing the non-traditional methodologies and endpoints used in an experiment of nature to study the pathogenesis of common COPD
the respiratory safety assessment of Exubera • Appreciating the fact that the concept of protease-antiprotease
• Understanding the value of functional endpoint standardization imbalance, thought to be shared by alpha-1 antitrypsin deficiency
• Understanding the potential for systemic therapies delivered by and common COPD, has not resulted in effective drugs for COPD
inhalation to interact with other environmental respiratory exposures • Becoming familiar with protein misfolding, aggregation and
or therapies disposal, a new link between alpha-1 antitrypsin deficiency and
• Discussing the guidance for development of inhalable insulins that has common COPD
been adopted by the US FDA • Understanding that pharmacologically targeting protein misfolding
John Teeter, MD, Senior Director, Development Lead, and trafficking could lead to the development of novel drugs for
Respiratory/Diabetes Emerging Markets, Pfizer Inc. both alpha-1 antitrypsin deficiency and common COPD
Adam Wanner, MD, Professor, Principal Investigator, University of
12:30 Networking Lunch Miami Miller School of Medicine
5:45 End of Day One
3 1-800-882-8684 • www.iqpc.com/us/asthma

4. Main Conference Day Two
Thursday, June 25, 2009
8:00 Registration and Coffee • Discussing recent insights into the molecular biology and
function of the airway nociceptor and its links to cough,
8:50 Welcome Address and Chairman’s Opening dyspnea and other respiratory symptoms
Remarks • Examining tetrodotoxin-resistant sodium channels and transient
receptor potential channels as emerging therapeutic targets for
9:00 Improving the Management of Patient Care in chronic respiratory diseases
Asthma • Identifying translational aspects of targeting ion channels for
• Improving communication and understanding between patients COPD symptom relief
and physicians M. Allen McAlexander, PhD, Investigator, Respiratory CEDD,
• Examining patient suggestions for improvements GlaxoSmithKline
• Improving education around the illness and treatment
• Discussing the benefits of more than one pharmacological 2:15 Formulation, Generation and Delivery of
approach Respiratory Therapeutic Aerosols to Rodents
Colin Scott, MD, Global Brand Medical Director, Novartis • Discussing the use of animal disease models as a tool for
assessing efficacy of inhaled pre-clinical drug candidates
9:45 Anti-C5 (Eculizumab) Treatment as Novel Therapy • Overview of instrumentation necessary to deliver dry powder
for Asthma (Case study) aerosols to rodents and estimated the dose delivered to the
• Displaying a proof of concept trial investigating the effect of C5 lungs
• Identifying ideal properties of inhaled respiratory drugs
inhibition on development of allergen-induced airway
• Displaying case study examples of using this model with clinical
responses in asthmatic subjects
• Discussing the treating Mild allergic asthmatics whom standard inhaled steroids
developed both early (EAR) and late asthmatic responses (LAR) Jonathan E. Phillips, Ph.D, Principal Scientist, Respiratory Drug
after allergen challenge Discovery, Schering-Plough Research Institute
• Understanding the primary endpoint which was the effect of
C5 inhibition on the development of LAR 3:00 Networking Break
• Discussing the development of eculizumab as a novel treatment
for severe persistent asthma 3:30 Leukocyte Proteases in Airways Diseases (Case
Yi Wang, PhD, Head, Preclinical Sciences, Alexion Study)
Pharmaceuticals Inc. • Protease-protease inhibitor imbalance contributes to airways
diseases such as asthma and COPD
10:30 Networking Break • Neutrophil derived Cathepsin G and mast cell derived chymase
and tryptase may be key enzymes contributing to these
11:00 Using Patents Strategically In Respiratory Product diseases
Lifecycle Management • Small molecule inhibitors of these enzymes have anti-
• Learning how innovators and generics are using patents to inflammatory properties and are effective in preclinical models
manage lifecycles of airways diseases
• Discussing patents on combination drugs in the current Lawrence de Garavilla, Ph.D., Research Fellow, Inflammation
environment and Pulmonary Diseases Team, Drug Discovery, Johnson &
• Using novel delivery systems—both pharmaceutical and Johnson Pharmaceutical Research and Development, L.L.C.
devices—as a basis for patent protection
• Getting competitive intelligence, patent strategy, and product 4:15 Leukotriene A4 Hydrolase Inhibitors and Airway
strategy to work together Inflammation (Case Study)
Bruce D. Sunstein, Co-founder, Partner, Bromberg & • Overview of leukotriene A4 hydrolase biology
Sunstein LLP • Efficacy of leukotriene A4 hydrolase inhibitors in preclinical
airway inflammation models
11:45 Novel Inhaled Drug Delivery Technology • Understanding the role of leukotrienes in chronic airway models
• Evaluating the effectiveness of Inhalation of bronchodilators • Displaying mechanisms of action of leukotriene A4 hydrolase
and glucocorticosteroids inhibitors
• Minimizing local (oropharyngeal) and systemic side-effects of Navin L. Rao, PhD, Senior Scientist, Drug Discovery,
drugs Inflammation, Johnson & Johnson
• Uncovering simple to use, portable, durable, unobtrusive and
cost effective medical device aspects 5:00 Functional Endpoints In Asthma
• Examining the pros and cons of the pressurized metered-dose • Discussing lung function use as a primary endpoint in asthma
inhaler (pMDI) - The most widely used delivery system clinical trials
• Discussing the increased-use of DPIs (Dry-powder Inhalers) to • Discussing relationships between, traditional and patient-
deliver asthma medications centered endpoints during treatment with different classes of
Speakers are to be announced. Please check the website medication
• Examining severe asthma indicated by poor lung function,
for speaker updates.
frequent symptoms or reliever use, night waking and
12:30 Networking Lunch exacerbations
• Understanding the relationship between end-points and
1:30 Novel Ion Channel Drug Development Strategies medication class
for the Treatment of COPD Symptoms • Identifying novel functional endpoints in Asthma with case
• Displaying the use of RNA interference for in vivo pre-clinical study examples
validation of ion channel targets in non-mouse species Chris O’Brien, PhD, Vice President, Respiratory & Inflammation
• Understanding automated patch-clamp and baculovirus-based Therapeutic Area, AstraZeneca
vectors for transient transfection as enabling technologies for
ion channel drug discovery 5:45 End Of Conference & Chairman’s Closing Remarks
4 1-800-882-8684 • www.iqpc.com/us/asthma

5. Post-Conference Workshops
Friday, June 26, 2009
9:00 am – 12:00 pm (Registration at 8:30 am) Coffee will be served 12.30 pm – 3.00 pm (Registration at 12:00 pm) Lunch included
A The Effective Use of Biomarkers in
Respiratory Drug Discovery
B Asthma and Allergy issues: Addressing
Approaches to Allergic Disorders
Studying clinical effects of new therapies on patients through Currently within the respiratory arena, there have been modern
electronic monitoring of lung function (FEV1) as well as misconceptions why asthma–related drug development
advanced lung function and exercise and challenge test has programs have not been pursued commercially in the form of
become possible. As a result of this., respiratory drug tackling other similar allergy-therapeutic disorders. Given that,
development companies are employing human whole blood there are many similarities between both asthma-based drug
flow cytometry and non-invasive sampling to assess therapeutics and many allergy-based drug development
pharmacodynamic effects of new therapies in phase I/II clinicial programs. This workshop will uncover and overview some of the
studies. Surrogate biomarkers in COPD may be assessed in novel approaches to these new drug development pipelines
blood, exhaled breath, induced sputum, bronchial mucosal focused on allergy therapeutics, and identify some of the most
biopsy, bronchoalveolar lavage (BAL), and through advanced commercially viable pipelines currently in development.
radiographic imaging.
What will be covered:
What will be covered: • Displaying novel approaches for identifying genes responsible
• Making a suited claim to the FDA for therapeutic purposes for allergic disorders
• Identifying and understanding new biotechnology agents and • Discussing standardized immuno-therapeutic approaches for
biomarkers for asthma allergies
• Studying clinical effects of new therapies on patients through • Evaluating unorthodox testing methods:
electronic monitoring of lung function (FEV1) 1. Vega (electro-diagnostic) testing
• Employing human whole blood flow cytometry and non- 2. Cytotoxic testing (quot;Bryan's testquot;) and the Alcat test
invasive sampling to assess pharmacodynamic effects of new 3. Iridology
therapies in phase I/II clinical studies 4. Kinesiology
• Relying on a collaboration between academics in clinical 5. IgG food antibody testing and other techniques
research, the pharmaceutical industry and regulatory • Developments in allergy elimination techniques - allergen
authorities immunotherapy
• Uncovering the link between allergic disorders and asthma
Workshop Leaders: approaches
Yi Wang, PhD, Head, Preclinical Sciences, Alexion
Pharmaceuticals Please check the website for up-to-date details about
Marianne Mann, MD, Clinical & Regulatory Drug Development the workshop.
Consultant
Please check the website for up-to-date details about
the workshop.
About the Media Partners
A major STM publisher, Bentham Science answers the information needs for the pharmaceutical, Bio-medical and medical research
community. Leading journals include Current Pharmaceutical Design (Impact Factor 4.8) and Current Medicinal Chemistry (Impact
Factor 4.9) FREE online journals & information: www.bentham.org
Since 1999, PharmiWeb.com has been bringing the latest news and developments in the pharmaceutical industry to a global
audience, now reaching close to a quarter of a million professionals. Sponsored by many of the world’s leading pharmaceutical
corporations, PharmiWeb.com is widely regarded as the leading pharma portal. To find out more about PharmiwWeb.com, and the
other offerings from PharmiWeb solutions, please visit www.pharmiwebsolutions.com.
Piribo is a UK-based independent online store supplying business information on the pharmaceutical and biotechnology industries.
The website now carries nearly 10,000 English language titles including, market reports, studies and books and is the UK's largest
online biopharma information store. www.piribo.com
Report Buyer is the intelligent way to buy market research online. Browse and choose from a current and comprehensive range of
specialised intelligence from leading publishers covering most industry and market sectors. Trusted by information professionals
across the world, Report Buyer’s mission is to help you find the right business intelligence. www.reportbuyer.com
5 1-800-882-8684 • www.iqpc.com/us/asthma

6. Asthma Gain valuable insights into new
groundbreaking advances within the
respiratory drug development market
& COPD
TM
June 24-26, 2009
Philadelphia, PA
REGISTRATION CARD (Email this form to info@iqpc.com or fax to 646-378-6025)
YES! Please register me for
❑ Conference Only ❑ All-Access Pass ❑ Workshops
Name ____________________________________________________________ Job Title _________________________________________________
Organization______________________________________________________ Approving Manager________________________________________
Address _____________________________________________ City________________________________________State__________Zip__________
Phone_____________________________________________E-mail____________________________________________________________________
❑ Please keep me informed via email about this and other related events.
❑ Check enclosed for $_________ (Payable to IQPC) ❑ Charge my ❑ Amex ❑ Visa ❑Mastercard ❑ Diners Club
Card #_______________________________Exp. Date___/___
❑ I cannot attend, but please keep me informed of all future events.
Registration Information
Qualified Pharmaceutical and Biotech Organizations:
PRICING Register by April 3, 2009 Register by April 17, 2009 Register by May 1, 2009 Register by May 29, 2009 Standard Price
Conference Only $1,199 (save $400) $1,299 (save $300) $1,399 (save $200) $1,499 (save $100) $1,599
All-Access Pass $1,999 (save $698) $2,099 (save $598) $2,199 (save $498) $2,299 (save $398) $2,399 (save $298)
Workshops $549 each $549 each $549 each $549 each $549 each
Others:
PRICING Register by May 1, 2009 Register by May 29, 2009 Standard Price
Conference Only $1,999 (save $600) $2,299 (save $300) $2,599
All-Access Pass $2,899 (save $798) $3,199 (save $498) $3,499 (save $198)
Workshops $549 each $549 each $549 each
See website at www.iqpc.com/us/asthma for an explanation of a Qualified Pharmaceutical and Biotech Organizations.
Please note multiple discounts cannot be combined. Reference: Please include the name of the attendee(s) and the event number: 17336.001
A $99 processing charge will be assessed to all registrations not Payment Policy: Payment is due in full at the time of registration and includes lunches, refreshment
accompanied by credit card payment at the time of registration. and detailed conference materials. Your registration will not be confirmed until payment is received
and may be subject to cancellation.
MAKE CHECKS PAYABLE IN U.S. DOLLARS TO: IQPC
* CT residents or people employed in the state of CT must add 6% sales tax. For IQPC’s Cancellation, Postponement and Substitution Policy, please visit
www.iqpc.com/cancellation
TEAM DISCOUNTS
or information on team discounts, please contact IQPC Customer Service at Note: Conference venue to be confirmed shortly. Please check www.iqpc.com/us/asthma for updated
1-800-882-8684. Only one discount may be applied per registrant. information.
Special Discounts Available: A limited number of discounts are available Special Dietary Needs: If you have a dietary restriction, please contact Customer Service at 1-800-882-
for the non-profit sector, government organizations and academia. For more 8684 to discuss your specific needs.
information, please contact customer service at 1-800-882-8684.
©2009 IQPC. All Rights Reserved. The format, design, content and arrangement of this brochure
Details for making payment via EFT or wire transfer: constitute a trademark of IQPC. Unauthorized reproduction will be actionable under the Lanham Act
JPMorgan Chase - Penton Learning Systems LLC dba IQPC: 957-097239 and common law principles.
ABA/Routing #: 021000021
6 1-800-882-8684 • www.iqpc.com/us/asthma